Pharmacokinetics and pharmacodynamics of antibacterial agents.
about
Methodology in improving antibiotic implementation policiesRight first time!Role of cephalosporins in the era of Clostridium difficile infectionEvaluation of Trimethoprim/Sulfamethoxazole (SXT), Minocycline, Tigecycline, Moxifloxacin, and Ceftazidime Alone and in Combinations for SXT-Susceptible and SXT-Resistant Stenotrophomonas maltophilia by In Vitro Time-Kill ExperimentsReducing hospital-acquired infections and improving the rational use of antibiotics in a developing country: an effectiveness study.Time-kill curve analysis and pharmacodynamic modelling for in vitro evaluation of antimicrobials against Neisseria gonorrhoeaeShaping Nanoparticles with Hydrophilic Compositions and Hydrophobic Properties as Nanocarriers for Antibiotic Delivery.Extensive antibiotic prescription rate among hospitalized patients in Uganda: but with frequent missed-dose days.Highly Fluorescent Ribonuclease-A-Encapsulated Lead Sulfide Quantum Dots for Ultrasensitive Fluorescence in Vivo Imaging in the Second Near-Infrared Window.Eravacycline Pharmacokinetics and Challenges in Defining Humanized Exposure In Vivo.Pharmacodynamic target attainment for various ceftazidime dosing schemes in high-flux hemodialysisA Population and Developmental Pharmacokinetic Analysis To Evaluate and Optimize Cefotaxime Dosing Regimen in Neonates and Young InfantsAntimicrobial susceptibility and minimal inhibitory concentration of Pseudomonas aeruginosa isolated from septic ocular surface disease in different animal species.Assessment of antibiotic resistance in Klebsiella pneumoniae exposed to sequential in vitro antibiotic treatments.Treatment of bacterial meningitis: an update.Phage therapy: eco-physiological pharmacology.Prediction of marbofloxacin dosage for the pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida by pharmacokinetic/pharmacodynamic modelling.Extended infusion of beta-lactam antibiotics: optimizing therapy in critically-ill patients in the era of antimicrobial resistance.Efficacy of Paromomycin-Chloroquine Combination Therapy in Experimental Cutaneous Leishmaniasis.Assessment of antivirulence activity of several d-amino acids against Acinetobacter baumannii and Pseudomonas aeruginosa.Daptomycin Pharmacokinetics and Pharmacodynamics in Septic and Critically Ill Patients.A comprehensive insight on ocular pharmacokinetics.Pharmacokinetic and pharmacodynamic characterization of ceftiofur crystalline-free acid following subcutaneous administration in domestic goats.Limitations of MIC as sole metric of pharmacodynamic response across the range of antimicrobial susceptibilities within a single bacterial species.Clinical implications of Pseudomonas aeruginosa location in the lungs of patients with cystic fibrosis.The intestinal microbiota: Antibiotics, colonization resistance, and enteric pathogens.New Potent Membrane-Targeting Antibacterial Peptides from Viral Capsid Proteins.Pharmacokinetics and in vivo efficacy of optimized oncocin derivatives.Saliva Versus Plasma Bioequivalence of Azithromycin in Humans: Validation of Class I Drugs of the Salivary Excretion Classification System.Review on Usage of Vancomycin in Livestock and Humans: Maintaining Its Efficacy, Prevention of Resistance and Alternative Therapy.Stress Introduction Rate Alters the Benefit of AcrAB-TolC Efflux Pumps.Role of enterohepatic recirculation in drug disposition: cooperation and complications.Statins: antimicrobial resistance breakers or makers?A novel medium size lactam ring analoges as antibacterial agents: Synthesis, biological evaluation and molecular docking studies.Proline-rich antimicrobial peptides show a long-lasting post-antibiotic effect on Enterobacteriaceae and Pseudomonas aeruginosa.Dosing strategies to optimize currently available anti-MRSA treatment options (Part 2: PO options).Targeting Wall Teichoic Acid in Situ with Branched Polyethylenimine Potentiates β-Lactam Efficacy against MRSA.Population pharmacokinetics and dosing optimisation of ceftazidime in infants.Considerable variation of trough β-lactam concentrations in older adults hospitalized with infection-a prospective observational study.A Physiologically Based Pharmacokinetic Perspective on the Clinical Utility of Albumin-Based Dose Adjustments in Critically Ill Patients.
P2860
Q26744801-E6DA2B3D-677B-4C87-9503-97CC4D375098Q28067972-208BD243-1BBE-44A7-8882-1F1089CC942AQ28078261-C5DFFE4A-C33C-4DE4-8BC1-98A51C152C5FQ28550910-2BE8FD95-5FED-48AE-A01A-E01D9D8DAF92Q35517526-632D5985-B20E-4374-AFF2-B2FF4CA4530BQ36136318-2F9D0C14-058D-4D94-9402-AE470617B3CBQ36786720-3A712EE0-810F-4D1D-9E76-930362399062Q36901503-0A4B554B-DE7D-4C43-B7F9-66E7990DF65BQ36907912-B673AF7C-D337-41A3-9F61-45210EE296FAQ37120165-DE2E6531-3A9A-4747-9BC0-EF2204C6FB77Q37335646-81430814-0BC0-4580-873F-7975B5F37C88Q37358644-54200FF2-481B-49DA-B1F9-229EB70FB55CQ37463976-B1CB0570-906A-40AC-89DC-31D307041706Q37490975-DC88CC9C-02A4-44D1-A4F6-6A46D21C0DA8Q38044024-0B92E5C9-41ED-4784-966D-EEE5DD1C48FEQ38230407-7239AD47-9207-4249-B523-BC538EE5627FQ38699731-E1C9169A-D5C3-4D27-B0E7-73EE8325CF78Q38705266-75B28BDE-0023-4C46-B65F-FB00ACBB870AQ38729021-D3A7991D-1562-4052-9293-559F8DACDDCEQ38747638-79FCB36F-277F-45A4-85D8-C7131765A66FQ38895642-B397213F-7C58-4262-8D44-E416FEC5302AQ38995367-8015E06C-6B40-43AF-9DCA-07B30A8235C1Q39108922-F7B462E7-C025-4C4A-AE78-6322D920DCB0Q39140300-DF9C6F10-246F-4E5E-8B71-FDDB2524AF87Q39218303-F4341CB5-E7C4-493D-8067-D6C94FAF3B86Q40063718-59F05127-E571-4744-9AAA-EBB181581D29Q40195691-EED741EF-46E3-4989-BC6B-0F120094467AQ40809842-FACBC1BE-E5DA-433B-94A2-DB041AE891C4Q42171540-5DC4B0A4-3575-4E80-B347-0C06A83B9786Q43378543-651EF462-827E-4B35-8E6F-2A18BA868F11Q46283683-1547A308-6888-4D99-B1B2-75C6BB7A7B00Q46578287-EB243243-3B42-4900-95B9-186BF3017C40Q47140385-BE226D52-9204-4850-A0A4-B5D504223738Q47159106-E28960CE-80AD-4DB3-A04C-74BD1ACF06B8Q47224789-DB59556D-1BF2-43EE-A98C-B78EE353B3D8Q47396324-907B32A4-789B-4737-9566-C8B42C3398E4Q47619127-76DA532A-3F4E-4708-923C-2AA742BED19EQ47645055-FD275559-8DF5-4050-9708-1A0E2A2B9A67Q48144933-36E3208E-6B1B-49AA-AAEE-C8AD8A865B92Q48154458-434067D6-20B6-4BD9-B6D8-4290AD9F66A5
P2860
Pharmacokinetics and pharmacodynamics of antibacterial agents.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Pharmacokinetics and pharmacodynamics of antibacterial agents.
@en
type
label
Pharmacokinetics and pharmacodynamics of antibacterial agents.
@en
prefLabel
Pharmacokinetics and pharmacodynamics of antibacterial agents.
@en
P2860
P1476
Pharmacokinetics and pharmacodynamics of antibacterial agents.
@en
P2093
Julie H Levison
Matthew E Levison
P2860
P304
791-815, vii
P356
10.1016/J.IDC.2009.06.008
P577
2009-12-01T00:00:00Z